Profund Advisors LLC reduced its stake in  Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 1.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,546 shares of the biopharmaceutical company’s stock after selling 671 shares during the period. Profund Advisors LLC’s holdings in Bristol-Myers Squibb were worth $3,061,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Dakota Wealth Management bought a new position in shares of  Bristol-Myers Squibb in the first quarter worth approximately $332,000.  Covestor Ltd lifted its position in  Bristol-Myers Squibb by 111.5% in the 1st quarter. Covestor Ltd now owns 2,052 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 1,082 shares in the last quarter.  NewEdge Advisors LLC boosted its stake in  Bristol-Myers Squibb by 53.2% during the 1st quarter. NewEdge Advisors LLC now owns 165,336 shares of the biopharmaceutical company’s stock valued at $12,075,000 after purchasing an additional 57,444 shares during the last quarter.  Ergoteles LLC bought a new stake in shares of  Bristol-Myers Squibb in the 1st quarter worth $1,997,000.  Finally, Mackenzie Financial Corp lifted its holdings in shares of  Bristol-Myers Squibb by 25.1% during the first quarter. Mackenzie Financial Corp now owns 338,563 shares of the biopharmaceutical company’s stock valued at $24,725,000 after purchasing an additional 68,018 shares in the last quarter. 75.51% of the stock is currently owned by institutional investors.

A number of equities analysts have weighed in on BMY shares. Cantor Fitzgerald assumed coverage on Bristol-Myers Squibb in a research report on Tuesday, January 17th. They issued an “overweight” rating and a $95.00 target price for the company. Wells Fargo & Company increased their price objective on shares of Bristol-Myers Squibb from $70.00 to $78.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 3rd. StockNews.com started coverage on shares of Bristol-Myers Squibb in a research report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Jefferies Financial Group began coverage on Bristol-Myers Squibb in a report on Monday, March 6th. They set a “hold” rating and a $62.00 price target on the stock. Finally, Atlantic Securities lifted their price objective on Bristol-Myers Squibb from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, February 3rd. One analyst  has rated the stock with a sell rating, seven have issued  a hold rating, seven have given a buy rating and one  has issued  a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $79.69.

In related news, CEO Giovanni Caforio sold 240,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, February 6th. The stock was sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the sale, the chief executive officer now owns 236,104 shares of the company’s stock, valued at approximately $17,625,163.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Giovanni Caforio sold 240,000 shares of the firm’s stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the completion of the transaction, the chief executive officer now directly owns 236,104 shares of the company’s stock, valued at $17,625,163.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ann Powell sold 11,183 shares of the business’s stock in a transaction on Monday, February 6th. The stock was sold at an average price of $74.69, for a total transaction of $835,258.27. Following the completion of the sale, the executive vice president now owns 23,043 shares in the company, valued at approximately $1,721,081.67. The disclosure for this sale can be found here. Company insiders own  0.08% of the company’s stock.

BMY stock opened at $70.23 on Wednesday. The business’s 50-day moving average price is $69.47 and its 200-day moving average price is $72.78. The stock has a market cap of $147.71 billion, a P/E ratio of 23.81, a PEG ratio of 1.55 and a beta of 0.45. The company has a quick ratio of 1.14, a current ratio of 1.25 and a debt-to-equity ratio of 1.13. Bristol-Myers Squibb has a twelve month low of $65.28 and a twelve month high of $81.43.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last issued its quarterly earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.71 by $0.11. The business had revenue of $11.41 billion for the quarter, compared to the consensus estimate of $11.20 billion. Bristol-Myers Squibb had a net margin of 13.71% and a return on equity of 51.60%. The company’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.83 earnings per share.  On average, equities research analysts forecast that  Bristol-Myers Squibb will post 7.98 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Monday, April 10th will be issued a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, April 6th. This represents a $2.28 dividend on an annualized basis and a yield of 3.25%. Bristol-Myers Squibb’s dividend payout ratio  is presently 77.29%.

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Get Rating).

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.